ID   IMDH_CRYPV              Reviewed;         400 AA.
AC   Q8T6T2;
DT   22-FEB-2012, integrated into UniProtKB/Swiss-Prot.
DT   01-JUN-2002, sequence version 1.
DT   07-APR-2021, entry version 105.
DE   RecName: Full=Inosine-5'-monophosphate dehydrogenase {ECO:0000303|PubMed:15269207};
DE            Short=IMP dehydrogenase {ECO:0000303|PubMed:15269207};
DE            Short=IMPD;
DE            Short=IMPDH {ECO:0000303|PubMed:15269207};
DE            EC=1.1.1.205 {ECO:0000269|PubMed:15269207};
GN   ORFNames=56k.02, cgd6_20;
OS   Cryptosporidium parvum.
OC   Eukaryota; Sar; Alveolata; Apicomplexa; Conoidasida; Coccidia;
OC   Eucoccidiorida; Eimeriorina; Cryptosporidiidae; Cryptosporidium.
OX   NCBI_TaxID=5807;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=Iowa;
RX   PubMed=11959921; DOI=10.1073/pnas.092525699;
RA   Striepen B., White M.W., Li C., Guerini M.N., Malik S.B., Logsdon J.M. Jr.,
RA   Liu C., Abrahamsen M.S.;
RT   "Genetic complementation in apicomplexan parasites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 99:6304-6309(2002).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Iowa;
RX   PubMed=12869580; DOI=10.1101/gr.1555203;
RA   Bankier A.T., Spriggs H.F., Fartmann B., Konfortov B.A., Madera M.,
RA   Vogel C., Teichmann S.A., Ivens A., Dear P.H.;
RT   "Integrated mapping, chromosomal sequencing and sequence analysis of
RT   Cryptosporidium parvum.";
RL   Genome Res. 13:1787-1799(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=HNJ-1;
RA   Yamagishi J., Wakaguri H., Sugano S., Kawano S., Fujisaki K., Sugimoto C.,
RA   Watanabe J., Suzuki Y., Kimata I., Xuan X.;
RT   "Construction and analysis of full-length cDNA library of Cryptosporidium
RT   parvum.";
RL   Submitted (FEB-2011) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   PROTEIN SEQUENCE OF 2-11, FUNCTION, CATALYTIC ACTIVITY, BIOPHYSICOCHEMICAL
RP   PROPERTIES, SUBUNIT, ACTIVITY REGULATION, AND MASS SPECTROMETRY.
RX   PubMed=15269207; DOI=10.1074/jbc.m407121200;
RA   Umejiego N.N., Li C., Riera T., Hedstrom L., Striepen B.;
RT   "Cryptosporidium parvum IMP dehydrogenase: identification of functional,
RT   structural, and dynamic properties that can be exploited for drug design.";
RL   J. Biol. Chem. 279:40320-40327(2004).
RN   [5]
RP   X-RAY CRYSTALLOGRAPHY (3.19 ANGSTROMS).
RX   PubMed=20052976; DOI=10.1021/ja909947a;
RA   Macpherson I.S., Kirubakaran S., Gorla S.K., Riera T.V., D'Aquino J.A.,
RA   Zhang M., Cuny G.D., Hedstrom L.;
RT   "The structural basis of Cryptosporidium-specific IMP dehydrogenase
RT   inhibitor selectivity.";
RL   J. Am. Chem. Soc. 132:1230-1231(2010).
RN   [6]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 1-89 OF 135-400 IN COMPLEX WITH
RP   IMP.
RX   PubMed=23668331; DOI=10.1021/jm400241j;
RA   Gorla S.K., Kavitha M., Zhang M., Chin J.E., Liu X., Striepen B.,
RA   Makowska-Grzyska M., Kim Y., Joachimiak A., Hedstrom L., Cuny G.D.;
RT   "Optimization of benzoxazole-based inhibitors of Cryptosporidium parvum
RT   inosine 5'-monophosphate dehydrogenase.";
RL   J. Med. Chem. 56:4028-4043(2013).
CC   -!- FUNCTION: Catalyzes the conversion of inosine 5'-phosphate (IMP) to
CC       xanthosine 5'-phosphate (XMP), the first committed and rate-limiting
CC       step in the de novo synthesis of guanine nucleotides, and therefore
CC       plays an important role in the regulation of cell growth.
CC       {ECO:0000269|PubMed:15269207}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=H2O + IMP + NAD(+) = H(+) + NADH + XMP; Xref=Rhea:RHEA:11708,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:57464,
CC         ChEBI:CHEBI:57540, ChEBI:CHEBI:57945, ChEBI:CHEBI:58053;
CC         EC=1.1.1.205; Evidence={ECO:0000269|PubMed:15269207};
CC   -!- COFACTOR:
CC       Name=K(+); Xref=ChEBI:CHEBI:29103;
CC         Evidence={ECO:0000250|UniProtKB:P20839};
CC   -!- ACTIVITY REGULATION: Mycophenolic acid (MPA) is a non-competitive
CC       inhibitor that prevents formation of the closed enzyme conformation by
CC       binding to the same site as the amobile flap. In contrast, mizoribine
CC       monophosphate (MZP) is a competitive inhibitor that induces the closed
CC       conformation. MPA is a potent inhibitor of mammalian IMPDHs but a poor
CC       inhibitor of the bacterial enzymes. MZP is a more potent inhibitor of
CC       bacterial IMPDH. Resistant to mycophenolic acid (MPA) inhibition
CC       (PubMed:15269207). {ECO:0000250|UniProtKB:P20839,
CC       ECO:0000269|PubMed:15269207}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=29 uM for Inosine 5'-phosphate {ECO:0000269|PubMed:15269207};
CC         KM=150 uM for NAD(+) {ECO:0000269|PubMed:15269207};
CC   -!- PATHWAY: Purine metabolism; XMP biosynthesis via de novo pathway; XMP
CC       from IMP: step 1/1. {ECO:0000305|PubMed:15269207}.
CC   -!- SUBUNIT: Homotetramer. {ECO:0000269|PubMed:15269207}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:P20839}.
CC   -!- MASS SPECTROMETRY: Mass=42904; Method=MALDI;
CC       Evidence={ECO:0000269|PubMed:15269207};
CC   -!- MISCELLANEOUS: Cryptosporidium IMPDH was acquired through lateral
CC       transfer from eubacteria, and predictably the sensitivity to MPA
CC       differs from that of mammalian IMPDH forms. This divergence of parasite
CC       and host enzymes is exploited to design more potent parasite-specific
CC       inhibitors. {ECO:0000305|PubMed:15269207}.
CC   -!- SIMILARITY: Belongs to the IMPDH/GMPR family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF426177; AAL83208.1; -; Genomic_DNA.
DR   EMBL; BX538350; CAD98604.1; -; Genomic_DNA.
DR   EMBL; FX115298; BAJ77401.1; -; mRNA.
DR   EMBL; FX115945; BAJ78048.1; -; mRNA.
DR   PDB; 3FFS; X-ray; 3.19 A; A/B/C/D=1-400.
DR   PDB; 4IXH; X-ray; 2.10 A; A/B/C/D=1-89, A/B/C/D=135-400.
DR   PDB; 4QJ1; X-ray; 2.42 A; A/B/C/D=1-400.
DR   PDB; 4RV8; X-ray; 2.05 A; A/B/C/D=1-89, A/B/C/D=135-400.
DR   PDBsum; 3FFS; -.
DR   PDBsum; 4IXH; -.
DR   PDBsum; 4QJ1; -.
DR   PDBsum; 4RV8; -.
DR   SMR; Q8T6T2; -.
DR   BindingDB; Q8T6T2; -.
DR   ChEMBL; CHEMBL6145; -.
DR   BRENDA; 1.1.1.205; 1728.
DR   SABIO-RK; Q8T6T2; -.
DR   UniPathway; UPA00601; UER00295.
DR   EvolutionaryTrace; Q8T6T2; -.
DR   GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR   GO; GO:0003938; F:IMP dehydrogenase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0006177; P:GMP biosynthetic process; IEA:UniProtKB-KW.
DR   CDD; cd00381; IMPDH; 1.
DR   InterPro; IPR005990; IMP_DH.
DR   InterPro; IPR015875; IMP_DH/GMP_Rdtase_CS.
DR   InterPro; IPR001093; IMP_DH_GMPRt.
DR   Pfam; PF00478; IMPDH; 1.
DR   PIRSF; PIRSF000130; IMPDH; 1.
DR   PROSITE; PS00487; IMP_DH_GMP_RED; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Cytoplasm; Direct protein sequencing; GMP biosynthesis;
KW   Metal-binding; NAD; Oxidoreductase; Potassium; Purine biosynthesis.
FT   CHAIN           1..400
FT                   /note="Inosine-5'-monophosphate dehydrogenase"
FT                   /id="PRO_0000415682"
FT   NP_BIND         212..214
FT                   /note="NAD"
FT                   /evidence="ECO:0000250|UniProtKB:P50097"
FT   REGION          252..254
FT                   /note="IMP binding"
FT                   /evidence="ECO:0000269|PubMed:23668331"
FT   REGION          275..276
FT                   /note="IMP binding"
FT                   /evidence="ECO:0000269|PubMed:23668331"
FT   REGION          299..303
FT                   /note="IMP binding"
FT                   /evidence="ECO:0000269|PubMed:23668331"
FT   ACT_SITE        219
FT                   /note="Thioimidate intermediate"
FT                   /evidence="ECO:0000250|UniProtKB:P50097"
FT   ACT_SITE        315
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P9WKI7"
FT   METAL           214
FT                   /note="Potassium; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:P50097"
FT   METAL           216
FT                   /note="Potassium; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:P50097"
FT   METAL           219
FT                   /note="Potassium; via carbonyl oxygen"
FT                   /evidence="ECO:0000250|UniProtKB:P50097"
FT   METAL           383
FT                   /note="Potassium; via carbonyl oxygen; shared with
FT                   tetrameric partner"
FT                   /evidence="ECO:0000250|UniProtKB:P50097"
FT   METAL           384
FT                   /note="Potassium; via carbonyl oxygen; shared with
FT                   tetrameric partner"
FT                   /evidence="ECO:0000250|UniProtKB:P50097"
FT   METAL           385
FT                   /note="Potassium; via carbonyl oxygen; shared with
FT                   tetrameric partner"
FT                   /evidence="ECO:0000250|UniProtKB:P50097"
FT   BINDING         163
FT                   /note="NAD"
FT                   /evidence="ECO:0000250|UniProtKB:P50097"
FT   BINDING         217
FT                   /note="IMP"
FT                   /evidence="ECO:0000269|PubMed:23668331"
FT   BINDING         329
FT                   /note="IMP"
FT                   /evidence="ECO:0000269|PubMed:23668331"
FT   STRAND          5..8
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           12..14
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          15..17
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           26..28
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          33..36
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          39..47
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   TURN            51..53
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           56..64
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          68..71
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          73..75
FT                   /evidence="ECO:0007744|PDB:4IXH"
FT   HELIX           77..88
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   TURN            132..134
FT                   /evidence="ECO:0007744|PDB:4QJ1"
FT   STRAND          138..141
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           146..155
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          158..163
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          167..169
FT                   /evidence="ECO:0007744|PDB:4QJ1"
FT   HELIX           170..182
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          186..192
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           195..203
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          207..211
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           221..224
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           231..242
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           243..245
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          249..253
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           258..266
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          270..274
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           276..279
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          281..284
FT                   /evidence="ECO:0007744|PDB:4QJ1"
FT   STRAND          288..291
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          294..300
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           305..309
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          332..336
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           341..358
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           364..370
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   STRAND          373..375
FT                   /evidence="ECO:0007744|PDB:4RV8"
FT   HELIX           378..384
FT                   /evidence="ECO:0007744|PDB:4IXH"
FT   STRAND          388..391
FT                   /evidence="ECO:0007744|PDB:4IXH"
SQ   SEQUENCE   400 AA;  43081 MW;  DAAF96B44050DD18 CRC64;
     MGTKNIGKGL TFEDILLVPN YSEVLPREVS LETKLTKNVS LKIPLISSAM DTVTEHLMAV
     GMARLGGIGI IHKNMDMESQ VNEVLKVKNW ISNLEKNEST PDQNLDKEST DGKDTKSNNN
     IDAYSNENLD NKGRLRVGAA IGVNEIERAK LLVEAGVDVI VLDSAHGHSL NIIRTLKEIK
     SKMNIDVIVG NVVTEEATKE LIENGADGIK VGIGPGSICT TRIVAGVGVP QITAIEKCSS
     VASKFGIPII ADGGIRYSGD IGKALAVGAS SVMIGSILAG TEESPGEKEL IGDTVYKYYR
     GMGSVGAMKS GSGDRYFQEK RPENKMVPEG IEGRVKYKGE MEGVVYQLVG GLRSCMGYLG
     SASIEELWKK SSYVEITTSG LRESHVHDVE IVKEVMNYSK
//
